AI for Pharma & Life Sciences
AI for pharma and life sciences, built to reach GxP production
Put ML, retrieval and agents to work across discovery, trials, regulatory, manufacturing quality and commercial, inside GxP controls so the output holds up in an audit. Governed by design, not governed later.
By 2028, more than 70% of the healthcare and lab environment is forecast to embrace AI (Gartner via LabVantage, 2026).
- 40+ products since 2017
- 20+ engineers
- 5.0 on Clutch
- 4.8 on Google
- 93% on-time
- UK, EU and USA
Last updated: November 2026
AI for pharma and life sciences means putting machine learning, retrieval and agents to work across discovery, clinical development, regulatory affairs, manufacturing quality and commercial, inside GxP controls so the output holds up in an audit. The value is in the workflows a regulated organisation can actually run, not a demo.
JoulesLabs is a product and systems engineering partner that builds pharma AI governed by design and ships the last mile from pilot to validated production. One scope note up front: we have not shipped a pharma AI agent in production, and our first client agents are at proof-of-concept, so this page describes our approach and our regulated-build track record (40+ product builds since 2017), not a pharma case study. JoulesLabs' CEO signs this page for teams in the UK, EU, GCC and USA.
The EMA and FDA published ten joint Guiding Principles of Good AI Practice in Drug Development on 14 January 2026, so governed AI is now the regulators' stated expectation (EMA and FDA, January 2026).
Reviewed by Arifur Rahman Naim, CEO, JoulesLabs
Last updated: November 2026
Governed by design Why does pharma AI now have to be governed by design?
Two 2026 regulatory moves made governance a design requirement, not an add-on.
The EMA and FDA jointly published ten Guiding Principles of Good AI Practice in Drug Development on 14 January 2026 (EMA and FDA). The EU AI Act's high-risk obligations apply from 2 December 2027 for Annex III systems and from 2 August 2028 for AI inside regulated medical devices (Regulation (EU) 2026/1744). GMP Annex 22 on AI in manufacturing is in revision after a 2025 consultation that drew about 1,300 comments, with the final text expected by the end of 2026 (EMA, February 2026).
The point is not fear. A governed build is the one you can actually scale, because it is the one that survives an inspection.
The map Which pharma and life-sciences workflows can AI move into production first?
- VALUE AREAS
- 6
- PRODUCTS SINCE 2017
- 40+
- PHARMA AI AGENT SHIPPED YET
- 0
Six workflow areas carry most of the production-ready demand, and each maps to a specific build capability.
Regulatory & pharmacovigilance
Safe to startDocument classification, submission drafting and case processing, via document AI for regulatory and pharmacovigilance.

Supply chain
Safe to startDemand forecasting and cold-chain assurance, via predictive AI for pharma supply chain.

Discovery & clinical trials
Build nextMolecule screening, target prioritisation and trial patient matching, via ML model development for discovery and trials. Discovery and trial models are the most mature of the six, and the ones with the longest validation history.

Manufacturing quality
Build nextVisual QA and process control in GxP manufacturing, via computer vision for GxP manufacturing quality.

Agentic operations
You stay in controlHuman-in-the-loop orchestration of R&D and quality workflows, via agentic systems for pharma.

Commercial
You stay in controlHCP engagement and self-service analytics, built on the same capabilities.

- Safe to start
- Build next
- You stay in control
A pharma pilot stops at the validation gate, not at the model. The notebook works, then someone asks for the context of use, the data lineage and the change record, and none of it exists. We write those three documents before the first model run, so the pilot is already the controlled system a QA team can inspect.
How do you take a pharma AI pilot into GxP production without failing validation?
Most pharma AI never leaves the pilot, and the reason is rarely the model. It is data architecture, validation evidence and the gap between a notebook and a controlled system. The bottleneck is organisational readiness and data architecture, not algorithmic sophistication. The honest sequence is readiness check first, governed pilot second, production only when the validation evidence exists. Getting that last mile is pilot-to-production rescue work, with agentic systems for pharma where orchestration is needed.
The wedge How do you keep pharma AI inspection-ready under the EMA-FDA principles and the EU AI Act?
Inspection-ready AI means the governance is built into the system: a documented context of use, data lineage, version control, human oversight and evidence a regulator can read.
The EMA-FDA principles name a risk-based approach, a clear context of use, adherence to standards such as GxP, and data governance and documentation across the lifecycle (EMA and FDA, 14 January 2026). A governed build is where a pharma AI programme wins, because it is the one that scales past the first site. It is AI security and governance work.
Inspection-ready means a regulator can read the system without us in the room. Every output carries its model version, its input data and the name of the person who approved it. The context of use is written down and the model stays inside it. If an inspector asks why, the log answers before we do.
Where to start Where should your pharma team start with AI?
Start with the workflow where your data is ready and the regulatory risk is understood, not the one that looks most advanced. Fragmented data is the usual bottleneck, so data readiness, regulated governance and an agentic architecture are the three capabilities to check first. Score a candidate use case on three axes, then take the recommended first step.
| Candidate use case | Data readiness | Regulatory-risk class | Recommended first step |
|---|---|---|---|
| Pharmacovigilance case triage | Medium | Supporting (not device) | A governed pilot on a bounded case type |
| Trial patient matching | Medium to high | Supporting, PII-sensitive | A readiness assessment on the EHR data first |
| Manufacturing visual QA | High (if line data exists) | GxP manufacturing control | A scoped pilot with validation evidence |
| Regulatory submission drafting | High (document-rich) | Supporting, human-reviewed | A governed pilot with a reviewer in the loop |
If you want help scoring your own, that is what the AI production readiness assessment is for.
Why JoulesLabs Why build pharma AI with JoulesLabs rather than a platform vendor?
JoulesLabs is a product and systems engineering partner that ships the last mile from pilot to governed production, with the IP staying yours. The honest position: we have not yet shipped a pharma or life-sciences AI agent in production, and our first client agents are at proof-of-concept. Our evidence is 40+ shipped product builds since 2017 and regulated-platform work in other sectors (for example the FundedNext trading platform, built end to end and serving 700,000+ users in 100+ countries), offered as method and track record, not as a pharma reference. In place of a borrowed case study, a first project is scoped to de-risk it:
You own the IP
The code and the models.
A scoped pilot
With a fixed outcome.
A parallel run
Against your current process before cutover.
Milestone billing
Tied to delivery.
Pharmacovigilance case triage is the first workflow we would propose to most sponsors, because case volume is high, the documents are structured and a reviewer already signs every case. First engagements are typically USD 20,000 to 50,000, scoped to the work.
Clients keep the code, the models and the validation evidence. A platform vendor rents you the model and keeps the evidence on their side, so every audit and every re-validation runs through them. With us, the IP and the documentation sit in your repository, and you can change vendor without starting the validation again.
Start where your data is ready and the risk is understood
Score your candidate use cases, pick the one that can reach validated production first, and run a governed pilot. A short call, or the free readiness assessment, is the fastest way to decide.
Start with a free readiness assessmentNo obligation. You leave with a where-to-start read scored on data readiness and regulatory risk.
FAQ Pharma AI questions buyers ask before they commit
Has JoulesLabs shipped a pharma AI agent in production?
No. First client agents are at proof-of-concept stage. This page describes our approach and our regulated-build track record, not a pharma deployment, and we offer a scoped, de-risked first build.
How do you keep AI inspection-ready?
Governance is built into the system: a documented context of use, data lineage, version control, human oversight and evidence a regulator can read, against the EMA-FDA principles, the EU AI Act and GMP Annex 22.
Which markets do you serve?
JoulesLabs delivers from Dhaka, Bangladesh for clients in the UK, EU, GCC and USA, and this page is scoped to those four markets.
What does a first engagement cost, and do we own it?
A first engagement is typically USD 20,000 to 50,000, scoped to the work, and you own the code and models we build.
How fast can a pilot run?
It depends on the data and the regulatory-risk class. We start with a readiness check and a bounded, governed pilot rather than an open program. A bounded pharmacovigilance or document pilot typically produces its first validation evidence within one quarter; a GxP manufacturing use case takes longer because the validation package is larger.
Governance by design is what lets pharma AI scale. A model with a written context of use, data lineage and a human approver passes validation once and then runs on every line and in every market. A model without them passes a demo and stops there. We build the governed version first.

